Advanced Magnetics targets pancreas:
This article was originally published in Clinica
Executive Summary
Diagnostic imaging of the pancreas is the initial aim of an R&D project between Advanced Magnetics and Massachusetts General Hospital. The product development agreement, whereby MGH will receive a minimum payment of $300,000, covers organ-specific, receptor-directed, superparamagnetic iron oxides for use as MRI contrast agents. Initial collaboration will focus on the pancreas - an "extremely difficult" organ to image, says Advanced Magnetics. Cancer of the pancreas affects 40,000 Americans each year.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.